Abstract
Purpose: Response assessment in brain tumors is currently done with the 2D Response Assessment in Neuro-Oncology (RANO) criteria. However, bevacizumab-treated patients may show pseudoresponse on contrast enhanced T1w- (T1w+C), and more infiltrative growth on T2w/FLAIR images at recurrence. We assessed whether in recurrent glioblastoma volumetric methods improve assessment of progressive disease (PD) over the RANO criteria, by correlating PD with overall survival (OS), the golden endpoint in oncology studies.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call